Want to see ABT full AI Analyst Report?
ABT Stock Chart & Stats
$116.13
$2.31(2.29%)
At close: 4:00 PM EDT
$116.13
$2.31(2.29%)
Day’s Range― - ―
52-Week Range$81.97 - $132.03
Previous CloseN/A
Volume10.37M
Average Volume (3M)9.96M
Market Cap
$180.95B
Enterprise Value$185.82B
Total Cash (Recent Filing)$5.60B
Total Debt (Recent Filing)$32.61B
Price to Earnings (P/E)38.7
Beta0.08
Next Earnings
Jan 27, 2027EPS Estimate
1.64Next Dividend Ex-DateN/A
Dividend Yield2.41%
Share Statistics
EPS (TTM)3.11
Shares Outstanding1,730,383,300
10 Day Avg. Volume10,654,722
30 Day Avg. Volume9,958,673
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.20
Price to Sales (P/S)4.94
P/FCF Ratio29.60
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue3.99
Enterprise Value/Gross Profit7.02
Enterprise Value/Ebitda16.41
Forecast
1Y Price Target
$121.94Price Target Upside5.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)5.52
Revenue Forecast (FY)$49.99B
Bulls Say, Bears Say
Bulls Say
Diversified Healthcare PortfolioAbbott’s presence across four healthcare segments diversifies revenue sources and reduces reliance on any single product category. Recurring demand for diagnostics consumables, diabetes sensors, nutrition products, and medicines supports a broad, durable operating base over the next several quarters.
Strong Cash GenerationRobust and growing free cash flow gives Abbott substantial capacity to fund research, product launches, dividends, debt management, and selective acquisitions. Free cash flow also tracks earnings closely, indicating that reported profitability is converting into usable cash for strategic investment.
Innovation And Growth PipelineElevated R&D investment and a broad pipeline provide multiple avenues for future product-led growth across devices, diagnostics, and pharmaceuticals. Recent approvals and launches, including Libre Duo and electrophysiology products, demonstrate continued commercialization capability and portfolio renewal.
Bears Say
Higher LeverageThe sharp increase in debt reduces financial flexibility relative to prior periods and makes Abbott more dependent on sustained operating cash generation. Higher leverage can constrain capital allocation and increase sensitivity to refinancing costs or weaker operating conditions over the medium term.
Margin CompressionRecent margin deterioration indicates that earnings growth is not converting as efficiently as it did in 2025. If normalization or higher costs persist, lower profitability could limit internal funding for innovation and reduce the benefit of Abbott’s otherwise steady revenue expansion.
Diabetes Pricing And Reimbursement PressureSlower diabetes growth affects an important innovation-driven business and reflects both pricing pressure abroad and limited reimbursement access for a broader type 2 population. These constraints could temper sensor volume growth and reduce the near-term payoff from Abbott’s diabetes pipeline.
Abbott Laboratories News
ABT FAQ
What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest stock price was $81.97 and its highest was $132.03 in the past 12 months.
What is Abbott Laboratories’s market cap?
Abbott Laboratories’s market cap is $180.95B.
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s upcoming earnings report date is Jan 27, 2027 which is in 88 days.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Oct 21, 2026. The company reported $1.42 earnings per share for the quarter.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays a Quarterly dividend of $0.63 which represents an annual dividend yield of 2.41%. See more information on Abbott Laboratories dividends here
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is 1.64.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,730,383,300 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of $1.42 in its last earnings report. Following the earnings report the stock price went down -1.894%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Currently, no hedge funds are holding shares in ABT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abbott Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$121.94 (5.00% Upside)
$121.94 (5.00% Upside)
Blogger Sentiment
Bullish
ABT Sentiment 86%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $46.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.87%
12-Months-Change
Fundamentals
Return on Equity
9.12%
Trailing 12-Months
Asset Growth
―
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
ABT Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly constructive: Abbott delivered 7% sales growth, 9% EPS growth, margin expansion, broad segment growth, multiple product approvals and launches, and announced a strategic nutrition separation intended to improve the growth and margin profile of the remaining company. The main negatives were a reduced full-year revenue outlook, short-term electrophysiology and diabetes headwinds, cybersecurity-related disruption in cancer diagnostics, foreign-exchange pressure, and uncertainty around 2027 guidance and CMS reimbursement timing. Highlights significantly outweighed the lowlights.View all ABT earnings summariesABT Net sales Breakdown
12.49% Established Pharmaceutical Products
19.06% Nutritional Products
20.16% Diagnostic Products
48.25% Medical Devices
0.04% Other

ABT Stock 12 Month Forecast
Average Price Target
$121.94
▲(5.00% Upside)
Technical Analysis
Boston Scientific
―
Dexcom
―
Edwards Lifesciences
―
Medtronic
―
GE Healthcare Technologies Inc
―
Ownership Overview
0.48% Insiders
21.94% Mutual Funds
3.42% Other Institutional Investors
48.50% Public Companies and Individual Investors











